Per our directory, 450 Ventures invests at seed, Series A, and Series B+. It is a corporate venture arm rather than a traditional lead-check seed fund, so stage fit depends on strategic relevance to Blue Cross and Blue Shield of Alabama.

450 Ventures has not published a fixed public check-size range in our sources. As a strategic corporate investor, check size varies by round and partnership value; founders should not assume a standard venture check without talking to the team.

450 Ventures is based in Birmingham, AL, and is the corporate venture arm of Blue Cross and Blue Shield of Alabama. Investments are typically evaluated for strategic fit with a large regional payer, not only for financial return.

Our directory tags healthtech. The mandate centers on healthcare and health-tech companies that can matter to members, providers, or payer operations—fraud/abuse tooling, care access, and related digital health are examples of themes that have appeared in public portfolio signals.

Our directory lists no lead stages for 450 Ventures. Corporate venture arms often participate alongside a financial lead; founders should expect strategic co-investment rather than a default lead check.

Public reporting and company materials have associated 450 Ventures with health-tech names including Codoxo (healthcare fraud, waste, and abuse analytics) and Acclinate (clinical-trial diversity and community engagement). We do not yet have those startups fully profiled as investor-linked entries in our directory.

450 Ventures does not maintain a widely marketed standalone website in our sources; founders typically reach the team through Blue Cross and Blue Shield of Alabama corporate innovation channels, warm intros from Alabama health-tech operators, or existing syndicate partners. Lead with clear strategic value to a payer ecosystem.

We do not yet have a dedicated 450 Ventures article. For related context, see our healthtech industry hub and Birmingham investor coverage as those pages expand.